Follow the 에임드바이오 share price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are listed on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 에임드바이오 has logged 16 insider filings. The latest transaction was reported on 5 February 2026 (Sale). Among the most active insiders: 인터베스트. All data is accessible without an account.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
16 of 16 declarations
AimdBio is a company in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative biopharmaceutical solutions.